|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0032105,
umls-concept:C0033684,
umls-concept:C0038954,
umls-concept:C0086418,
umls-concept:C0145779,
umls-concept:C0160390,
umls-concept:C0205178,
umls-concept:C0376618,
umls-concept:C0441889,
umls-concept:C0547047,
umls-concept:C1257890,
umls-concept:C1272745,
umls-concept:C1517004,
umls-concept:C1749467
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2009-6-18
|
|
pubmed:abstractText |
In addition to the hyperactivation of the inflammatory cytokines, high-mobility group box-1 protein (HMGB1), recently identified as a lethal late-phase mediator is suspected to be closely correlated with the development of sepsis. Therefore, the therapeutic efficacy of recombinant human soluble thrombomodulin (ART-123) administration on the production of inflammatory cytokines and the plasma level of HMGB1 was investigated in experimental endotoxemia.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/ART123,
http://linkedlifedata.com/resource/pubmed/chemical/Antithrombin III,
http://linkedlifedata.com/resource/pubmed/chemical/HMGB1 Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Hbp1 protein, rat,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-1beta,
http://linkedlifedata.com/resource/pubmed/chemical/Lipopolysaccharides,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Hydrolases,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Thrombomodulin,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/antithrombin III-protease complex,
http://linkedlifedata.com/resource/pubmed/chemical/lipopolysaccharide, E. coli 026-B6
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1530-0293
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
37
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2181-6
|
|
pubmed:meshHeading |
pubmed-meshheading:19487933-Animals,
pubmed-meshheading:19487933-Antithrombin III,
pubmed-meshheading:19487933-Disease Models, Animal,
pubmed-meshheading:19487933-Endotoxemia,
pubmed-meshheading:19487933-HMGB1 Protein,
pubmed-meshheading:19487933-Interleukin-1beta,
pubmed-meshheading:19487933-Lipopolysaccharides,
pubmed-meshheading:19487933-Liver,
pubmed-meshheading:19487933-Liver Diseases,
pubmed-meshheading:19487933-Male,
pubmed-meshheading:19487933-Peptide Hydrolases,
pubmed-meshheading:19487933-Rats,
pubmed-meshheading:19487933-Rats, Sprague-Dawley,
pubmed-meshheading:19487933-Recombinant Proteins,
pubmed-meshheading:19487933-Thrombomodulin,
pubmed-meshheading:19487933-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia.
|
|
pubmed:affiliation |
Department of Surgery 1, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
|
|
pubmed:publicationType |
Journal Article
|
